IntelGenx Technologies Corp. (OTC:IGXT)
Industry: Services

OFF LIST - 579 consecutive market days: OFF LIST as of 08/12/2011 Through 11/14/2016

IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2008 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease. It is also developing INT0037/2013, INT0039/2013, INT0040/2014, INT0045/2018, INT0046/2018. The company has co-development and commercialization agreements with RedHill Biopharma Ltd., Par Pharmaceutical Companies, Inc., and Endo Ventures Ltd.; licensing, development, and supply agreement with Tilray, Inc., Gensco Pharma, and Chemo Group; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

Current Quote*
Last: $0.640
Change: -0.020
Book: $11.379
Volume: 62,210

As Of: 10/22 13:01 ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol IGXT

  • No BuyIns.Net Alerts Available for IGXT

Graphs for IGXT


3 Month Graph


6 Month Graph


1 Year Graph